• AstraZeneca reports positive Phase III overall‑survival results for sonesitatug vedotin in advanced/metastatic gastric cancer; trial met primary and key secondary OS endpoints, no new safety signals.
  • AstraZeneca (AZN) says its launch pricing now reflects the U.S. MFN policy. The company struck MFN pricing deals with the White House; lower EU prices may weigh on U.S. returns.
  • AstraZeneca (AZN) Q2 revenue $15.38B (+5% cc). Oncology sales +15% led by Tagrisso, Imfinzi. Net profit $2.51B. Core EPS $2.63 (+18% cc).
  • AstraZeneca (AZN): CARDIO-TTRansform Phase III for Wainua missed primary endpoint; Farxiga revenue pressured by generics; Elecoglipron showed positive Phase IIb and moved toward Phase III planning.
  • AstraZeneca (AZN) said its adult/adolescent TA-TMA Phase 3 missed the primary endpoint but showed a treatment trend. Company will pursue pediatric filings after a positive Phase 3 survival result.
  • AstraZeneca (AZN): 11 buys, 1 hold; median 12‑month price target $217, about 22% above last close $169.26.
  • AstraZeneca (AZN) will accelerate China collaborations, adopt a 'Chinese speed' approach and focus on simplification and core technologies to speed operations—news relevant to AZN traders.
  • AstraZeneca (AZN) reported stronger‑than‑expected Q2 profits. CFO said AI won’t directly cut jobs amid growth; CEO called job‑loss claims false, saying AI boosts employee output and quality.